| AIDS | Acquired immunodeficiency syndrome |
| WHO | World Health Organization |
| UNAIDS | The Joint United Nations Program on HIV/AIDS |
| HIV | Human immunodeficiency virus |
| HAART | Highly active antiretroviral therapy |
| ARV | Antiretroviral |
| CNS | Central nervous system |
| BBB | Blood–brain barrier |
| P-gp | P-glycoprotein |
| NLC | Nanostructured lipid carriers |
| ATZ | Atazanavir |
| SLN | Solid lipid nanoparticle |
| SNEDDS | Self-nanoemulsifying drug delivery system |
| SLB | Solid–liquid binary lipid |
| QbD | Quality by Design |
| BBD | Box–Behnken design |
| RSM | Response surface methodology |
| PDI | Polydispersity index |
| ZP | Zeta potential |
| EE | Entrapment efficiency |
| LC | Loading capacity |
| TEM | Transmission electron microscopy |
| DSC | Differential scanning calorimetry |
| PBS | Phosphate buffer saline |
| HPLC | High performance liquid chromatographic method |
| CLSM | Confocal laser scanning microscopy |
| MTT | Methylthiazoletetrazolium |
| H&E | Hematoxylin and eosin |
| CV | Cresyl violet |
| ANOVA | Analysis of variance (ANOVA |
| GRAS | Generally recognized as safe |
| HLB | Hydrophilic–lipophilic balance |